{"id":"https://openalex.org/W1968209682","doi":"https://doi.org/10.1158/1535-7163.targ-09-a16","title":"Abstract A16: Antitumor activity of CYT997: A phase II vascular disrupting agent administered orally in combination with cisplatin in a colon adenocarcinoma xenograft model","display_name":"Abstract A16: Antitumor activity of CYT997: A phase II vascular disrupting agent administered orally in combination with cisplatin in a colon adenocarcinoma xenograft model","publication_year":2009,"publication_date":"2009-12-01","ids":{"openalex":"https://openalex.org/W1968209682","doi":"https://doi.org/10.1158/1535-7163.targ-09-a16","mag":"1968209682"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.targ-09-a16","doi":"https://doi.org/10.1158/1535-7163.targ-09-a16","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-09-a16","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101876467","display_name":"Andrew K. Powell","orcid":"https://orcid.org/0000-0002-9779-1122","observed_orcids":["https://orcid.org/0000-0002-9779-1122"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrew K. Powell","raw_affiliation_strings":["1 Cytopia Research Pty Ltd, Richmond, Victoria, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1 Cytopia Research Pty Ltd, Richmond, Victoria, Australia;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013810423","display_name":"Steven D. Shnyder","orcid":"https://orcid.org/0000-0002-4647-2340","observed_orcids":["https://orcid.org/0000-0002-4647-2340"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Steven D. Shnyder","raw_affiliation_strings":["2 Institute of Cancer Therapeutics, Bradford, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2 Institute of Cancer Therapeutics, Bradford, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043541980","display_name":"Patricia A. Cooper","orcid":"https://orcid.org/0000-0002-6875-0313","observed_orcids":["https://orcid.org/0000-0002-6875-0313"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Patricia A. Cooper","raw_affiliation_strings":["2 Institute of Cancer Therapeutics, Bradford, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2 Institute of Cancer Therapeutics, Bradford, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Stuart Nelson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stuart Nelson","raw_affiliation_strings":["2 Institute of Cancer Therapeutics, Bradford, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2 Institute of Cancer Therapeutics, Bradford, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064831071","display_name":"Christopher J. Burns","orcid":"https://orcid.org/0000-0002-4463-4916","observed_orcids":["https://orcid.org/0000-0002-4463-4916"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christopher J. Burns","raw_affiliation_strings":["1 Cytopia Research Pty Ltd, Richmond, Victoria, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1 Cytopia Research Pty Ltd, Richmond, Victoria, Australia;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028681659","display_name":"Rose Fida","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rose Fida","raw_affiliation_strings":["1 Cytopia Research Pty Ltd, Richmond, Victoria, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1 Cytopia Research Pty Ltd, Richmond, Victoria, Australia;","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112420442","display_name":"Gregg D. Smith","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gregg D. Smith","raw_affiliation_strings":["1 Cytopia Research Pty Ltd, Richmond, Victoria, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1 Cytopia Research Pty Ltd, Richmond, Victoria, Australia;","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"8","issue":"12_Supplement","first_page":"A16","last_page":"A16"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Synthesis and biological activity","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vascular-disrupting-agents","display_name":"vascular disrupting agents","score":0.9039999842643738},{"id":"https://openalex.org/keywords/colon-adenocarcinoma","display_name":"colon adenocarcinoma","score":0.9160000085830688},{"id":"https://openalex.org/keywords/cisplatin-combination-therapy","display_name":"cisplatin combination therapy","score":0.8519999980926514},{"id":"https://openalex.org/keywords/oral-administration","display_name":"oral administration","score":0.6830000281333923},{"id":"https://openalex.org/keywords/tumor-necrosis","display_name":"tumor necrosis","score":0.8740000128746033},{"id":"https://openalex.org/keywords/metronomic-dosing","display_name":"metronomic dosing","score":0.8130000233650208},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.8579999804496765},{"id":"https://openalex.org/keywords/tumor-vasculature-targeting","display_name":"tumor vasculature targeting","score":0.5379999876022339},{"id":"https://openalex.org/keywords/antiproliferative-activity","display_name":"antiproliferative activity","score":0.6359999775886536},{"id":"https://openalex.org/keywords/doxorubicin","display_name":"doxorubicin","score":0.46299999952316284},{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":0.9959999918937683},{"id":"https://openalex.org/keywords/vincristine","display_name":"vincristine","score":0.9779999852180481}],"concepts":[{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6925657987594604},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.6445351839065552},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.6379877328872681},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6096476316452026},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5356796383857727},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.46400681138038635},{"id":"https://openalex.org/C2777056448","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral administration","level":2,"score":0.46159929037094116},{"id":"https://openalex.org/C503630168","wikidata":"https://www.wikidata.org/wiki/Q178069","display_name":"Necrosis","level":2,"score":0.4127439558506012},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3269144892692566},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.25564461946487427},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2116169035434723},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.10444644093513489},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1535-7163.targ-09-a16","doi":"https://doi.org/10.1158/1535-7163.targ-09-a16","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-09-a16","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2221199809","https://openalex.org/W2149213586","https://openalex.org/W2608632102","https://openalex.org/W2240153941","https://openalex.org/W2228134409","https://openalex.org/W2127771250","https://openalex.org/W2901020741","https://openalex.org/W1992375630","https://openalex.org/W3010436989","https://openalex.org/W4230882666"],"abstract_inverted_index":{"Abstract":[0],"CYT997":[1,28,62,136,152,167,221,266,314,359,367,394],"is":[2,12,386,395],"an":[3],"orally":[4],"bioavailable":[5],"small":[6],"molecule":[7],"vascular-disrupting":[8],"agent":[9],"(VDA)":[10],"that":[11,27,366],"currently":[13],"being":[14],"investigated":[15],"in":[16,66,84,114,154,193,217,240,246,270,299,319,347,397],"Phase":[17],"II":[18],"clinical":[19],"studies.":[20],"In":[21],"vitro":[22],"efficacy":[23,107,143,310,392],"studies":[24,71],"have":[25],"demonstrated":[26,65,207],"exhibits":[29,368],"potent":[30],"antiproliferative":[31],"activity":[32,60],"against":[33],"the":[34,67,215,235,300,304,312,334,340,348],"DLD-1":[35,101],"cell":[36],"line":[37],"(IC50":[38,50],"21":[39],"nM),":[40],"with":[41,86,100,181,220,223,291,321,333,399],"a":[42,87,155,165,292,376],"similar":[43],"potency":[44],"to":[45,116,147,258,284,307,354],"doxorubicin,":[46],"paclitaxel":[47],"and":[48,57,83,106,126,130,142,157,175,203,370],"vincristine":[49],"8":[51],"\u2013":[52,250],"53":[53],"nM).":[54],"The":[55,309],"antitumor":[56],"vascular":[58,121,171,189],"targeting":[59],"of":[61,70,119,151,161,214,243,265,273,279,303,311,324,337],"has":[63],"been":[64],"current":[68],"series":[69],"following":[72,375,381],"alternate":[73],"dosing":[74,315],"regimens":[75],"(single":[76],"dose":[77,229,379],"vs":[78],"metronomic":[79,313,383],"sub-maximal":[80,382],"daily":[81],"dose)":[82],"combination":[85,320,349,398],"standard":[88],"chemotherapeutic":[89],"agent,":[90],"cisplatin.":[91],"Female":[92],"Balb/C":[93],"immunodeficient":[94],"nude":[95],"mice":[96,218],"were":[97,134],"implanted":[98],"subcutaneously":[99],"human":[102],"colon":[103],"adenocarcinoma":[104],"fragments":[105],"was":[108,144,173,191,289,317,345],"assessed":[109,318],"via":[110],"tumor":[111,120,162,216,244,274,305,342],"caliper":[112],"measurements,":[113],"addition":[115],"histological":[117,205],"assessment":[118],"shutdown":[122,160,172,190,242,252,272,282],"(Hoechst":[123],"33342":[124],"staining)":[125],"necrotic":[127,301],"area":[128,302],"(haematoxylin":[129],"eosin":[131],"staining).":[132],"Animals":[133],"administered":[135],"(dihydrochloride":[137],"salt)":[138],"by":[139],"oral":[140,228,263,378],"gavage":[141],"expressed":[145],"relative":[146,306,353],"vehicle":[148,182,224,259,285],"control.":[149,225,308],"Administration":[150],"resulted":[153,239,269],"time":[156],"concentration":[158],"dependent":[159],"vasculature.":[163],"Following":[164],"single":[166,227,377],"administration":[168,264,323],"(40":[169],"mg/kg),":[170],"extensive":[174],"rapid":[176,369],"(ca":[177,199,210,233,295],"95%":[178],"ablation":[179],"compared":[180,222,257,283],"control":[183],"at":[184,230,253],"1h":[185],"post-dose;":[186],"p<0.01).":[187],"Significant":[188],"maintained":[192],"tumors":[194],"4":[195],"days":[196,278],"post":[197],"treatment":[198,280],"67%":[200],"shutdown;":[201],"p<0.05)":[202,213,298],"subsequent":[204],"examination":[206],"increased":[208,390],"necrosis":[209],"280%":[211],"increase;":[212,297],"treated":[219],"A":[226],"10":[231,277],"mg/kg":[232,327],"1/5th":[234],"maximum":[236],"tolerated":[237],"dose),":[238],"statistically-significant":[241],"vasculature":[245,275],"this":[247],"model":[248],"(61":[249],"94%":[251],"1":[254],"h":[255],"post-dose":[256],"control;":[260,286],"p<0.05).":[261],"Daily":[262],"(10":[267],"mg/kg/day)":[268],"sustained":[271],"over":[276],"(57%":[281],"p<0.05),":[287],"which":[288],"associated":[290,332],"significant":[293],"increase":[294],"44%":[296],"schedule":[316],"weekly":[322],"cisplatin":[325,338,355],"(6":[326],"i.p.).":[328],"Despite":[329],"some":[330],"toxicity":[331],"second":[335],"cycle":[336],"administration,":[339],"greatest":[341],"growth":[343],"delay":[344],"observed":[346],"group":[350],"(2.7":[351],"days),":[352],"(1.9":[356],"days)":[357,361],"or":[358,380],"(1.8":[360],"alone.":[362],"These":[363],"findings":[364],"demonstrate":[365],"long":[371],"lasting":[372],"antivascular":[373],"effects":[374],"dosing.":[384],"There":[385],"clear":[387],"potential":[388],"for":[389],"anti-tumor":[391],"when":[393],"dosed":[396],"other":[400],"common":[401],"anticancer":[402],"therapies.":[403],"Citation":[404],"Information:":[405],"Mol":[406],"Cancer":[407],"Ther":[408],"2009;8(12":[409],"Suppl):A16.":[410]},"counts_by_year":[{"year":2012,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2016-06-24T00:00:00"}